Tagged with IMI

Colombia Tecnoquimicas (TQ), the largest domestic player in Colombia’s USD 4.6 billion pharma market, announced a swathe of manufacturing investments in late 2019, taking its spending on plants and equipment in the 2018-2022 period to over USD 200 million.   According to Company President Francisco José Barberi, TQ’s investments will expand…

Romania Valentina Băicuianu and Adrian Grecu of the APMGR, share their insights on the deteriorating environment for generics in Romania, with unfavourable pricing methodology and a rising and an unpredictable clawback tax. They reveal the solutions that the generics industry has proposed to authorities and outline their continued endeavours to convince…

Generics Arun Narayan of Medicines for Europe’s Value Added Medicines Group has been working to promote the benefits of value added medicines and how real-world evidence must be considered. In a recent interview with PharmaBoardroom he elaborated on what some countries are already doing to adopt Value Added Medicines and the…

Belgium Joris Van Assche, managing director of the Belgian association for accessible medicines, Medaxes, highlights the need for a stronger policy to create a more positive environment for generic and biosimilar medicines. He also outlines the important role the off-patent sector plays in the long-term sustainability of Belgium’s universal healthcare system.…

Czech Republic Milan Černek, country manager of Mylan in the Czech Republic, provides expert insights into current trends in the Czech Republic’s generics and biosimilars markets, describes the affiliate’s strategy to continue growing and reinforces the company’s commitment to providing high-quality modern treatments.   The Czech Republic is a perfect example of…

China The Chinese healthcare market has transformed dramatically in the past few years. There have been many reforms centred around the country’s vision of becoming a healthcare technology powerhouse in the next couple of decades and ‘innovation’ has become a buzzword touted by both foreign and local players alike. But in…

Europe Isabell Remus, chair of the Biosimilar Medicines Group at Medicines for Europe outlines the issues that need to be addressed to keep driving biosimilar uptake in Europe.   Since the first treatment was approved in 2006, Europe has been at the vanguard of the biosimilar medicines sector, approving more treatments…

USA The AAM’s Chip Davis gives an account of his agenda for 2020, how the association is driving policy in a complex healthcare environment of multiple public and private actors and offers insight as to why there is great room for improvement in the uptake of biosimilar drugs.   The question,…

India Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia and New Zealand markets.   We see ourselves as a company that has great capabilities and is investing big time…

Hungary Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s first company-developed biosimilar in Japan.   Our advancement in biotechnology has been a key development for Gedeon Richter this year…

Hungary István Hodász, CEO of Egis Pharmaceuticals PLC, introduces the longstanding history of the company and its positioning as a leading manufacturer of value-added generics with a strong presence in the CEE market. Hodász goes on to highlight the company’s recent milestones, including manufacturing investments, portfolio acquisitions, new therapeutic area strategies,…

Czech Republic Sandoz’s Jiří Hanzlík, country head for the Czech Republic, evaluates the Czech affiliate’s role in contributing to the success of Sandoz globally as well as its position in the country. He delves into the growth of their biosimilars business — its portfolio share increased from eight to 15 percent in…